Immune cells with membrane-bound IL-21 and preparation method and application thereof

By expressing membrane-bound IL-21 (mbIL-21) on the NK cell membrane, the problems of short survival time and immunosuppression risk in NK cell therapy are solved, significantly improving the amplification and killing ability of NK cells, and achieving more efficient tumor treatment.

CN117645669BActive Publication Date: 2024-11-01NEUKIO BIOTHERAPEUTICS (SHANGHAI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211042674.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-08-29
Publication Date
2024-11-01
Estimated Expiration
2042-08-29

AI Technical Summary

Technical Problem

Existing NK cell therapies in clinical applications are subject to the short survival time of NK cells and the challenge of producing large doses, which affect the efficacy, and IL-2 treatment may trigger immunosuppression.

Method used

A membrane-bound IL-21 (mbIL-21) recombinant protein was developed, and it was expressed on the NK cell membrane through genetic engineering, promoting the division, proliferation and prolonging survival of NK cells and reducing the risk of secreted IL-21.

Benefits of technology

It significantly enhances the amplification ability and lethality of NK cells in vivo and in vitro, extends the survival time of NK cells, improves the efficacy, and reduces the dependence on exogenous cytokines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0003821031670000011
    Figure HDA0003821031670000011
  • Figure HDA0003821031670000012
    Figure HDA0003821031670000012
  • Figure HDA0003821031670000021
    Figure HDA0003821031670000021
Patent Text Reader

Abstract

The present invention discloses immune cells with membrane-bound IL-21, a preparation method thereof and an application thereof. Specifically, the present invention discloses a membrane-bound IL-21 (mbIL-21) and an application thereof in immunotherapy. The mbIL-21 of the present invention can enhance the amplification ability and lethality of specific immune cells, thereby enhancing the effect of NK cell therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of cell therapy, and in particular to immune cells with membrane-bound IL-21, and a preparation method and application thereof. Background Art

[0002] The homeostasis of the immune system relies on two major components: the innate and adaptive immune responses, which are regulated by a range of cytokines. One of the most extensively studied cytokines is the cytokine receptor gamma chain (γc) family, which includes IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. This group of cytokines displays a broad range of pleiotropic effects, modulating both the innate and adaptive immune systems, collectively promoting the development of various immune cell populations, regulating cell differentiation, and promoting survival or inducing apoptosis depending on the cellular context.

[0003] Among cell therapies, NK cell therapy is a promising anticancer strategy, but the widespread clinical success of NK cell therapy has been limited in part by the challenges of manufacturing large doses of NK cells, which may be required for clinical efficacy.

[0004] In addition, studies have shown that compared with T cells, NK cells have a shorter survival in the host, which may affect the effectiveness of NK cells in killing tumors. Combined treatment with IL-2 can prolong the survival of NK cells in the host to a certain extent, but IL-2 can also cause a large number of Treg cells that exert an immunosuppressive effect to proliferate.

[0005] Therefore, there is an urgent need in the art to develop NK cells with longer in vivo persistence and higher efficacy. Summary of the invention

[0006] The purpose of the present invention is to provide NK cells with longer in vivo duration and higher therapeutic effect, and their preparation method and application.

[0007] In a first aspect of the present invention, a recombinant protein is provided, wherein the recombinant protein is membrane-bound IL-21 (mbIL-21), and the recombinant protein has the following characteristics:

[0008] (a) The recombinant protein has the structure shown in Formula I:

[0009] Z1-Z2-Z3-Z4 (I)

[0010] In the formula,

[0011] Z1 is a signal peptide or none;

[0012] Z2 is IL-21 polypeptide;

[0013] Z3 is the CD8 hinge region;

[0014] Z4 is the CD8 transmembrane region;

[0015] “-” represents a peptide bond or a connecting peptide.

[0016] (b) The recombinant protein has the sequence shown at positions 1-249 or positions 25-249 of SEQ ID No: 1; or has the sequence shown at positions 1-246 or positions 22-246 of SEQ ID No: 2.

[0017] In another preferred embodiment, the Z2 comprises a wild-type or mutant IL-21 element.

[0018] In another preferred embodiment, the Z2 includes IL-21 elements of human and non-human mammals.

[0019] In another preferred embodiment, the Z3 and Z4 are each independently wild type or mutant type.

[0020] In another preferred embodiment, the Z3 and Z4 are independently derived from human and non-human mammals.

[0021] In another preferred embodiment, the Z1 comprises the following sequence:

[0022] IL-21SP MRSSPGNMERIVICLMVIFLGTLV SEQ ID No:3 CD8αSP MALPVTALLLPLALLLHAARP SEQ ID No:4 CSF2SP MWLQSLLLLGTVACSIS SEQ ID No:5 DAP12SP MGGLEPCSRLLLLPLLLAVSG SEQ ID No:6 CD16SP MWQLLLPTALLLLVSA SEQ ID No:7 CD56SP MLQTKDLIWTLFFLGTAVS SEQ ID No:8 IL-8SP MTSKLAVALLAAFLISAALC SEQ ID No:9

[0023] The second aspect of the present invention provides an isolated polynucleotide encoding the recombinant protein described in the first aspect of the present invention.

[0024] The third aspect of the present invention provides a vector, wherein the vector contains the polynucleotide of the second aspect of the present invention.

[0025] In another preferred embodiment, the vector includes a plasmid or a viral vector.

[0026] In another preferred embodiment, the vector is selected from the following group: retroviral vector, adenoviral vector, lentiviral vector, AAV vector.

[0027] In a fourth aspect, the present invention provides a genetically engineered cell, wherein the genetically engineered cell is selected from the group consisting of embryonic stem cells, mesenchymal stem cells, iPSC cells (induced pluripotent stem cells), NK cells, T cells, lymphocytes, or a combination thereof.

[0028] In another preferred embodiment, the genetically engineered cells include NK cells, T cells or lymphocytes.

[0029] And the genetically engineered cells have the following characteristics:

[0030] (a) comprising the vector according to the third aspect of the present invention; or

[0031] (b) The polynucleotide according to the second aspect of the present invention is integrated into its genome.

[0032] In another preferred embodiment, the genetically engineered cells express membrane-bound IL-21 (mbIL-21) and the mbIL-21 protein exists on the cell membrane.

[0033] The fifth aspect of the present invention provides a pharmaceutical composition, which comprises the genetically engineered cell described in the fourth aspect of the present invention and a pharmaceutically acceptable carrier thereof.

[0034] In another preferred embodiment, the genetically engineered cells include NK cells, T cells or lymphocytes.

[0035] In another preferred embodiment, the pharmaceutical composition is used for cell therapy.

[0036] In another preferred embodiment, the cell therapy is used to treat tumors.

[0037] The sixth aspect of the present invention provides a use of the genetically engineered cells described in the fourth aspect of the present invention, wherein the genetically engineered cells are used to prepare drugs for immunotherapy.

[0038] The seventh aspect of the present invention provides a cellular immunotherapy, which comprises the steps of: administering the genetically engineered cells described in the fourth aspect of the present invention to a patient, wherein the genetically engineered cells contain the vector described in the third aspect of the present invention, or the polynucleotide described in the second aspect of the present invention is integrated into their genome.

[0039] In another preferred embodiment, the genetically engineered cells express membrane-bound IL-21 (mbIL-21) and the mbIL-21 protein exists on the cell membrane.

[0040] In another preferred embodiment, the genetically engineered cells are selected from the following group: embryonic stem cells, mesenchymal stem cells, iPSC cells, NK cells, T cells, lymphocytes or a combination thereof.

[0041] In another preferred embodiment, the patient is a tumor patient, preferably suffering from a tumor selected from the following group: hematological tumors, lung cancer, liver cancer, neuroblastoma, ovarian tumors, rhabdomyosarcoma, breast cancer, gastric cancer, digestive tract tumors, kidney cancer, and prostate cancer.

[0042] In another preferred embodiment, the patient is a tumor patient, preferably an early tumor patient who does not need radiotherapy or chemotherapy, or an advanced tumor patient who cannot undergo radiotherapy or chemotherapy.

[0043] In another preferred embodiment, the immunotherapy is administered by intravenous injection or local tissue injection.

[0044] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 A schematic diagram of the structure of the recombinant protein mbIL-21 is shown.

[0046] Figure 2 The isolation, culture and identification of NK cells are shown.

[0047] Figure 3 The expression of mbIL-21 on the surface of NK cells was detected.

[0048] Figure 4 It was shown that mbIL-21 promotes NK cell division and proliferation.

[0049] Figure 5 It was shown that mbIL-21 stimulates NK cell proliferation.

[0050] Figure 6 It was shown that mbIL-21 promoted the phosphorylation of STAT3 in NK cells.

[0051] Figure 7 The effect of mbIL-21 on CD226 expression is shown. DETAILED DESCRIPTION

[0052] After extensive and in-depth research, the inventors unexpectedly found that a recombinant protein with a special structure, membrane-bound IL-21 (mbIL-21), is expressed in a manner fixed to the cell membrane surface of NK and other lymphocytes, thereby significantly promoting the division and proliferation of NK cells, prolonging the in vivo persistence of NK cells, and significantly reducing or eliminating the potential risks of secretory IL-21 that are not conducive to NK cell therapy, thereby enhancing the efficacy of NK cell immunotherapy. On this basis, the present invention was completed.

[0053] the term

[0054] In order that the present disclosure may be more readily understood, certain terms are first defined. As used in this application, unless otherwise expressly provided herein, each of the following terms shall have the meaning given below.

[0055] The term "about" can refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined.

[0056] The term "administering" refers to the physical introduction of the product of the invention into a subject using any of a variety of methods and delivery systems known to those skilled in the art, including intravenous, intratumoral, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, such as by injection or infusion.

[0057] Membrane-bound IL-21

[0058] As used herein, the terms "protein of the present invention", "membrane-bound IL-21", "membrane-bound IL-21 protein", "membrane-bound IL-21 of the present invention", "mbIL-21 protein" and the like are used interchangeably and refer to the recombinant protein described in the first aspect of the present invention.

[0059] Typically, the membrane-bound IL-21 protein of the present invention has the structure shown in Formula I.

[0060] NK cells

[0061] As used herein, the terms "NK cells", "memory NK cells", "natural killer cells", "natural killer (NK) cells", "NK", etc. are used interchangeably to refer to a major class of immune effector cells that protect the body from viral infection and tumor cell invasion through non-antigen specific pathways. Engineered (genetically modified) NK cells may acquire new functions, including the ability to specifically recognize tumor antigens and have enhanced anti-tumor cytotoxic effects.

[0062] Carrier

[0063] The present invention provides vectors containing the nucleotides of the present invention. Vectors derived from retroviruses such as lentiviruses are suitable tools for achieving long-term gene transfer because they allow transgenes to be stably integrated into the cell genome for a long time and replicate with the replication of the daughter cell genome. Lentivirus vectors have advantages over vectors derived from oncogenic retroviruses such as murine leukemia viruses because they can transduce non-proliferating cells and have the advantage of low immunogenicity.

[0064] Genetically engineered cells expressing membrane-bound IL-21

[0065] The present invention provides a genetically engineered cell expressing the membrane-bound IL-21 of the present invention, wherein the genetically engineered cell is selected from the following group: embryonic stem cells, mesenchymal stem cells, iPSC cells (induced pluripotent stem cells), NK cells, T cells, lymphocytes, or a combination thereof.

[0066] Pharmaceutical composition

[0067] The present invention provides a pharmaceutical composition containing the engineered immune cells of the present invention, and a pharmaceutically acceptable carrier, diluent or excipient thereof.

[0068] In one embodiment, the preparation is a liquid preparation. Preferably, the preparation is an injection.

[0069] In one embodiment, the formulation may include a buffer such as neutral buffered saline, sulfate buffered saline, etc.; a carbohydrate such as glucose, mannose, sucrose or dextran, mannitol; a protein; a polypeptide or an amino acid such as glycine; an antioxidant; a chelating agent such as EDTA or glutathione; and a preservative. The formulation of the present invention is preferably formulated for intravenous administration or local tissue administration.

[0070] Therapeutic applications

[0071] The present invention includes therapeutic applications of cells (e.g., NK cells) transduced with vectors (e.g., lentiviral vectors) containing the recombinant proteins of the present invention. NK cells can target surface markers of tumor cells, and the proliferation efficiency of transduced NK cells and their killing ability against tumor cells are significantly improved.

[0072] The main advantages of the present invention include:

[0073] (a) The mbIL-21 of the present invention can significantly enhance the proliferation and killing ability of NK cells in vivo and in vitro, thereby enhancing the effect of NK cell therapy.

[0074] (b) The mbIL-21 nucleotide fragment of the present invention can be inserted into the expressible site of pluripotent stem cells (iPSC, ESC, etc.) by gene editing, and the differentiated immune cells represented by NK cells have stronger proliferation and killing capabilities.

[0075] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.

[0076] Example 1 Design of recombinant protein mb-IL21

[0077] The main structure of the recombinant protein mb-IL21 in this example is as follows Figure 1 As shown, the signal peptide sequence of IL21, the hinge sequence of CD8 and the transmembrane sequence of CD8 (TM) were used.

[0078] The amino acid sequence of mbIL-21 in this example is shown in SEQ ID No: 1 or 2:

[0079] IL21SP-IL21-GGGGS-CD8 hinge-CD8TM

[0080] MRSSPGNMERIVICLMVIFLGTLVHKSSSQGQDRHMIRMRQLIDIVDQLKNYVNDLVPEFLPAPEDVETNCEWSAFSCFQKAQLKSANTGNNERIINVSIKKLKRKPPSTNAGRRQKHRLTCPSC DSYEKKPPKEFLERFKSLLQKMIHQHLSSRTHGSEDSGGGGSPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVV*

[0081] (SEQ ID No:1)

[0082] CD8aSP-IL21-GGGGS-CD8 hinge-CD8TM

[0083] MALPVTALLLPLALLLHAARPHKSSSQGQDRHMIRMRQLIDIVDQLKNYVNDLVPEFLPAPEDVETNCEWSAFSCFQKAQLKSANTGNNERIINVSIKKLKRKPPSTNAGRRQKHRLTCPSCD SYEKKPPKEFLERFKSLLQKMIHQHLSSRTHGSEDSGGGGSPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVV*

[0084] (SEQ ID No:2)

[0085] The sequence of the recombinant protein mb-IL21 of this example is an artificially synthesized nucleotide sequence corresponding to SEQ ID No: 1 or 2.

[0086] In addition, mb-IL21 with a P2A sequence was constructed and mbIL-21 was linked to the mCherry reporter gene through P2A, so that the stability of the entire expression system can be monitored more easily and quickly during the early evaluation and screening of the design schemes of these molecules.

[0087] Example 2 Isolation, culture, expansion and identification of NK cells

[0088] NK cells are isolated from human peripheral blood mononuclear cells (PBMCs). After culture and expansion, the obtained NK cells are identified.

[0089] The identification results are as follows Figure 2 The results showed that CD3 + CD56 + Greater than 90% of the NK cell population.

[0090] Example 3 Preparation of genetically engineered NK cells expressing mbIL-21

[0091] In order to verify the function of mbIL-21, the coding sequence of mbIL-21 was cloned into a retroviral vector, packaged to produce retrovirus, and NK cells were infected. Subsequently, the expression of IL-21 on the surface of NK cell membrane was detected by flow cytometry, and it was found that the expression ratio of IL-21 on NK cells from different donors was between 25% and 40%. In this example, the mbIL-21 used was IL21SP-IL21-GGGGS-CD8 hinge-CD8TM (SEQ ID No: 1).

[0092] result

[0093] like Figure 3 As shown, NK cells expressing mbIL-21 on the cell surface were obtained.

[0094] Example 4 Effect of mbIL-21 on NK cell proliferation

[0095] In order to verify the effect of mbIL-21 on NK cell proliferation, in this example, NK-Ctrl and NK-mbIL-21 cells were labeled with CFSE and verified under culture conditions without IL-2 (W / O IL-2) and low concentration of IL-2 (20U / ml IL-2), respectively.

[0096] In this example, the mbIL-21 used was IL21SP-IL21-GGGGS-CD8hinge-CD8TM (SEQ ID No: 1).

[0097] The method is as follows: 1. Take out 6E6 NK-Ctrl or NK-mbIL-21 cells, centrifuge at 300g for 5 minutes at room temperature, and discard the supernatant. 2. Add 10mL of room temperature PBS, gently blow off the cells, centrifuge at 300g for 5 minutes at room temperature, and discard the supernatant. 3. Add 6μL CellTrace TM CFSE dye was diluted into 6mL PBS to prepare a mixed solution. 4. Resuspend the cells with the mixed solution in the above step, with 1mL of mixed solution for every 1E6 cells. 5. Place in a 37℃ incubator and stain for 20min away from light. 6. Add 5 times the volume of complete culture medium and continue to place in a 37℃ incubator and avoid light for 5min to terminate the staining. 7. Centrifuge at 300g for 5min at room temperature and discard the supernatant. 7. Add 10mL of room temperature PBS to wash the cells 2-3 times. 8. Resuspend the cells with 12mL of NK culture medium, adjust the cell density to 5E5 / ml, add to a 12-well plate, place in a 37℃ incubator and culture for 3-5 days before testing. .

[0098] result

[0099] like Figure 4 and Figure 5 As shown. On day 0, the CFSE signal intensities of NK-Ctrl and NK-mbIL-21 were consistent. On days 3 and 4, in the absence of IL-2 culture conditions, mbIL-21 can significantly promote the division and proliferation of NK cells. In the presence of IL-2, since IL-2 itself can significantly stimulate NK cell proliferation, mbIL-21 can no longer play an additional role at this time. After modification with mbIL-21 designed by the present invention, NK cells can proliferate without relying on exogenous cytokines.

[0100] Example 5 Effect of mbIL-21 on STAT3 phosphorylation

[0101] STAT3 plays a major role in the signal transduction and proliferation of IL-21. In this example, in order to detect the effect of mbIL-21 on STAT3 phosphorylation, the expression of phosphorylated STAT3 (pSTAT3) in NK-Ctrl and NK-mbIL-21 was detected by flow cytometry, and the mean fluorescence intensity (MFI) of pSTAT3 was calculated.

[0102] In this example, the mbIL-21 used was IL21SP-IL21-GGGGS-CD8hinge-CD8TM.

[0103] The method is as follows: 1. Use 10mL BD Pharmingen TM Wash the cells twice with Stain Buffer (Cat. No. 554656). 2. Dilute the required amount of BD Phosflow ELISA kit in a 1:5 ratio with deionized or distilled water. TM Lyse / FixBuffer (5× concentrate), and then preheat the solution to 37°C. 3. Use 500 μL of preheated 1× BD Phosflow TM 4. Use 1 mL of BD Pharmingen TM Wash the cells twice with Stain Buffer (Cat. No. 554656). 5. Before use, add BD Phosflow TM 6. Cool Perm Buffer III at -20°C or 4°C. TM Slowly resuspend the cells in PermBufferⅢ (Cat.No.558050) and incubate on ice for 30 min. 7. Use 1 mL BD Pharmingen TM Wash the cells twice with Stain Buffer (Cat. No. 554656). TM Resuspend the cells in Stain Buffer (FBS) and 647Mouse IgG2a IsotypeControl (Cat. No. 558053) and Alexa 647 mouse anti-Stat3 (pY705) antibody (Cat. No. 557815) was used for staining at room temperature in the dark for 30 minutes. TM Wash the cells once with Stain Buffer and then rinse with 200 μL BD Pharmingen TM Resuspend cells in Stain Buffer for flow cytometry analysis.

[0104] The results are as follows Figure 6 As shown, expression of mbIL-21 can significantly promote the phosphorylation of STAT3.

[0105] Example 6 Effect of mbIL-21 on CD226 expression

[0106] CD226, also known as DNAM-1, belongs to the immunoglobulin superfamily and is mainly expressed in NK cells, T cells, and some B cell subsets. The binding of CD226 on the surface of NK cells and ligands such as CD155 and CD112 on the surface of tumor cells can enhance the secretion of NK cell cytokines and cytotoxicity. Studies have found that during aging and the development of cancer, the expression of CD226 on the surface of NK cells gradually decreases, indicating that CD226 may mediate the immune surveillance function of NK cells. In addition, CD226 also plays an important role in maintaining the function of memory NK.

[0107] In this example, it was verified whether mbIL-21 expressed by NK had an effect on CD226 expression, and the method was as follows: 1. Take 1E5-2E5 cells to be tested, centrifuge at 200g-400g, 4℃ for 5min, and discard the supernatant. 2. Add 200ul FACS Buffer (1% FBS dissolved in PBS) and wash once, centrifuge at 200g-400g, 4℃ for 5min, and discard the supernatant. 3. Add 100ul CD226 direct labeled antibody (1:100), mix by pipetting, and incubate at 4℃ for 30min-60min. 4. After incubation, add 200ul / well FACS Buffer, centrifuge at 200g-400g, 4℃ for 5min, and discard the supernatant. 5. Repeat step 4 twice. 6. After washing, add 200ul / well FACS Buffer to resuspend and detect by flow cytometry.

[0108] In this example, the mbIL-21 used was IL21SP-IL21-GGGGS-CD8hinge-CD8TM.

[0109] The results are as follows Figure 7 As shown, mbIL-21 expressed on the surface of NK cells unexpectedly and significantly promoted the expression of CD226 on the surface of NK cells.

[0110] discuss

[0111] Cytokines such as IL-2 and IL-15 have many effects on immune cells such as NK.

[0112] Although IL-2 is used to prolong the survival time of NK cells in the host, it can also cause a large number of Treg cells that play an immunosuppressive role to proliferate. However, in clinical applications, it has been found that intravenous injection of IL-2 can cause symptoms such as fever and vomiting, and can also lead to water and salt metabolism disorders and abnormal functions of the kidneys, liver, heart, and lungs; the most common and most serious is capillary leak syndrome, which forces patients to terminate treatment.

[0113] IL-15 also has some similar functions to IL-2, including stimulating the proliferation of activated T cells, generating cytotoxic effector T cells, and activating and maintaining NK cells. Unlike IL-2, it is generally believed that IL-15 does not cause a large number of Treg cells to proliferate. In addition, IL-15 also plays an important role in the generation and maintenance of memory NK cells. However, studies have found that under long-term in vitro expansion conditions, the long-term presence of IL-15 will cause NK cells to have an exhausted phenotype.

[0114] IL-21 activates the JAK-STAT, PI3K, and MAPK pathways. STAT3 plays a major role in the biological effects of IL-21, but STAT1 also contributes to the expression of genes regulated by IL-21. IL-21 plays an important role in regulating NK cell proliferation, killing activity, and memory. For example, IL-21 can promote the secretion of IFN-γ by NK cells. Using K562 cells expressing IL-21 as a trophoblast, a large number of highly activated NK cells can be expanded in vitro, and the exhaustion of NK cells that is prone to occur during culture can be improved.

[0115] The inventors unexpectedly discovered through research that by modifying IL-21 and making it fixedly expressed on the surface of specific cells to form membrane-bound IL-21 (mbIL-21), the proliferation ability of NK cells in vitro can be greatly enhanced, NK cell exhaustion can be reduced, and its life span in the host can be prolonged, thereby enhancing the killing ability of NK cells against tumor cells. In particular, the optimized mbIL-21 protein can significantly promote the proliferation of NK cells and the phosphorylation of intracellular signals such as STAT3, and has a very broad prospect for clinical application.

[0116] In addition, the mbIL-21 of the present invention can be used in combination with factors such as IL-12, IL-15, and IL-18 to jointly promote the production of memory NK cells.

[0117] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A recombinant protein, characterized in that The recombinant protein is membrane-bound IL-21 (mbIL-21), and the amino acid sequence of the recombinant protein is shown in SEQ ID NO:

1.

2. An isolated polynucleotide, characterized in that Encoding the recombinant protein according to claim 1.

3. A carrier, characterized in that The vector contains the polynucleotide according to claim 2.

4. The vector according to claim 3, characterized in that The vector is selected from the group consisting of a plasmid and a viral vector.

5. The vector according to claim 3, characterized in that The vector is selected from the group consisting of a retroviral vector, an adenoviral vector, and an AAV vector.

6. The vector according to claim 3, characterized in that The vector is a lentiviral vector.

7. A genetically engineered cell, characterized in that: The genetically engineered cell contains the vector according to any one of claims 3 to 6, or the polynucleotide according to claim 2 is integrated into its genome.

8. The genetically engineered cell according to claim 7, wherein The genetically engineered cells are selected from the group consisting of embryonic stem cells, mesenchymal stem cells, iPSC cells (induced pluripotent stem cells), lymphocytes, or a combination thereof.

9. The genetically engineered cell according to claim 7, characterized in that The genetically engineered cells include NK cells and T cells.

10. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the genetically engineered cell according to any one of claims 7 to 9 and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition according to claim 10, characterized in that The genetically engineered cells include lymphocytes.

12. The pharmaceutical composition according to claim 10, characterized in that The genetically engineered cells include NK cells and T cells.

13. A use of the genetically engineered cell according to any one of claims 7 to 9, characterized in that: The genetically engineered cells are used to prepare drugs for immunotherapy.

14. Use of the vector according to any one of claims 3 to 6 or the polynucleotide according to claim 2, characterized in that: For use in the preparation of medicaments for immunotherapy.

15. The use according to claim 13, characterized in that The genetically engineered cells are selected from the group consisting of embryonic stem cells, mesenchymal stem cells, iPSC cells, lymphocytes, or a combination thereof.

16. The use according to claim 13, characterized in that The genetically engineered cells are selected from the following group: NK cells and T cells.

17. The use according to claim 13 or 14, characterized in that The drug is administered to a patient, which is a tumor patient.

18. The use according to claim 17, characterized in that The patient suffers from a tumor selected from the group consisting of hematological tumors, lung cancer, liver cancer, neuroblastoma, ovarian tumors, rhabdomyosarcoma, breast cancer, digestive tract tumors, kidney cancer, and prostate cancer.

19. The use according to claim 17, characterized in that The patient suffers from gastric cancer.